Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Phase I study of a CD19-directed CAR-T cell therapy for Relapsed/refractory mantle cell lymphomas(MCL)

Ping Yang, Jinjie Gao, Lan Luo, Weilong Zhang, Jing Wang, Hongmei Jing

Blood (2025) 146 (Supplement 1): 7125.

https://doi.org/10.1182/blood-2025-7125

Published: 2025

Journal Articles

Short-term follow-up results of ultra-low-dose radiotherapy for indolent B-cell lymphoma

Min Li, Ran Peng, Ping Yang, Fang Bao, Jijun Wang, Qihui Li, Hongmei Jing, Hao Wang

Blood (2025) 146 (Supplement 1): 7113.

https://doi.org/10.1182/blood-2025-7113

Published: 2025

Journal Articles

Genomic characterization uncovers molecular subtypes in Mantle Cell Lymphoma

Changjian Yan, Ping Yang, Jie Chen, Chaoling Wu, Xiaoyu Hao, Jing Wang, Mingxia Zhu, Yan Liu, Weilong Zhang, Hongmei Jing

Blood (2025) 146 (Supplement 1): 3590.

https://doi.org/10.1182/blood-2025-3590

Published: 2025

Journal Articles

Heterogeneous TP53 mutation subtypes define prognostic classification in Mantle Cell Lymphoma

Shuozi Liu, Ping Yang, Shaowei Zhou, Weilong Zhang, Jing Wang, Lingli Wang, Chunyuan Li, Yingtong Chen, Wenxin Qi, Hongmei Jing

Blood (2025) 146 (Supplement 1): 3589.

https://doi.org/10.1182/blood-2025-3589

Published: 2025

Journal Articles

Analysis of factors associated with clinical response in glofitamab's treatment of relapsed or refractory (R/R) large B-cell lymphoma

Lan Luo, Yaxin Zheng, Ping Yang, Xu Zhang, Fei Dong, Jijun Wang, Hongmei Jing

Blood (2025) 146 (Supplement 1): 7262.

https://doi.org/10.1182/blood-2025-7262

Published: 2025

Journal Articles

Efficacy and safety of zanubrutinib combined with reduced-dose bendamustine and Rituximab for eldly Mantle Cell Lymphoma: A retrospective analysis

Ping Yang, Shuozi Liu, Chuanyuan Li, Lan Luo, Weilong Zhang, Jing Wang, Hongmei Jing

Blood (2025) 146 (Supplement 1): 7097.

https://doi.org/10.1182/blood-2025-7097

Published: 2025

Journal Articles

Prognostic and therapeutic implications of the immune landscape in Mantle Cell Lymphoma

Changjian Yan, Chaoling Wu, Ping Yang, Xiaoyu Hao, Jie Chen, Jing Wang, Mingxia Zhu, Yan Liu, Hongmei Jing, Weilong Zhang

Blood (2025) 146 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2025-1821

Published: 2025

Journal Articles

Single-cell dissection of pathogenic T-cell response to tacrolimus in immune thrombocytopenia

Li-Ping Yang, Peng Zhao, Qiu-Sha Huang, Xiang-Yu Zhao, Qian Jiang, Ying-Jun Chang, Lanping Xu, Xiaojun Huang, Xiaohui Zhang

Blood (2025) 146 (Supplement 1): 3024.

https://doi.org/10.1182/blood-2025-3024

Published: 2025

Journal Articles

Teriflunomide, an oral dihydroorotate dehydrogenase inhibitor, in immune thrombocytopenia

Li-Ping Yang, Hai-Xia Fu, Mengtong Zang, Kexin Shen, Yuanyuan Zhang, Xiang-Yu Zhao, Qian Jiang, Ying-Jun Chang, Lanping Xu, Xiaojun Huang, Xiaohui Zhang

Blood (2025) 146 (Supplement 1): 1271.

https://doi.org/10.1182/blood-2025-1271

Published: 2025

Journal Articles

Robust assessment of early MRD levels could further improve treatment outcomes in low-risk patients of pediatric acute lymphoblastic leukemia: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL Study

Blood (2025) 146 (Supplement 1): 1550.

https://doi.org/10.1182/blood-2025-1550

Published: 2025

Journal Articles

The efficacy of Obinutuzumab , zanubrutinib combined with pomalidomide and Venetoclax for the treatment of high-risk mutated Mantle Cell Lymphoma (MCL): A prospective, open-label, single-arm study

Ping Yang, Jinjie Gao, Lan Luo, Weilong Zhang, Jing Wang, Hongmei Jing

Blood (2025) 146 (Supplement 1): 1530.

https://doi.org/10.1182/blood-2025-1530

Published: 2025

Journal Articles

Therapeutic preclinical study on the synergy between CD73 inhibitors and selinexor for managing multiple myeloma

Chun-Li Zhang, Qiuxia Wei, Nigmat Rahim, Gang Bian, Chaoling Wu, Jing Wang, Ping Yang, Jiahui Hua, Mingxia Zhu, Yingtong Chen, Yan Liu, Shuang Gao, Bing Hou, Weilong Zhang, Hongmei Jing

Blood (2025) 146 (Supplement 1): 7455.

https://doi.org/10.1182/blood-2025-7455

Published: 2025

Journal Articles

Baricitinib reveals LGALS3BP as a novel pathogenic factor and therapeutic target in immune thrombocytopenia

Kexin Shen, Jingli Han, Zhuo-Yu An, Peng Zhao, Hai-Xia Fu, Qiu-Sha Huang, Jin Wu, Li-Ping Yang, Yuanyuan Zhang, Ying-jun Chang, Xiangyu Zhao, Yu Wang, Lan-Ping Xu, Xiaojun Huang, Xiaohui Zhang

Blood (2025) 146 (Supplement 1): 846.

https://doi.org/10.1182/blood-2025-846

Published: 2025

Journal Articles

Imaging Activated Innate Immune Myeloid Cells in Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-Cell Therapy

Ajlan Al Zaki, Margie Sutton, Abdur Rehman, Cao Cuong Le, Seth Gammon, Arianna Napoli, Ping Yang, Neeraj Y. Saini, Sairah Ahmed, Ghayas C. Issa, Partow Kebriaei, Michael Davies, Elizabeth J. Shpall, Jeena Varghese, Lesley Flynt, Sattva S. Neelapu, David Piwnica-Worms

Blood (2024) 144 (Supplement 1): 3428.

https://doi.org/10.1182/blood-2024-211204

Published: 2024

Journal Articles

Clinical Application for Modification of the 2022 European Leukemianet Genetic Risk Stratification in Pediatric Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 4313.

https://doi.org/10.1182/blood-2024-201637

Published: 2024

Journal Articles

Selinexor Synergizes with Decitabine in Mantle Cell Lymphoma through MAPK Signaling Pathway

Yingtong Chen, Ping Yang, Weilong Zhang, Jing Wang, Shuang Gao, Yuan Yang, Shuozi Liu, Chunyuan Li, Hongmei Jing

Blood (2024) 144 (Supplement 1): 5845.

https://doi.org/10.1182/blood-2024-205492

Published: 2024

Journal Articles

UHRF1 Is a Promising Therapy Target in Aggressive Mantle Cell Lymphoma

Yuan Yang, Ping Yang, Weilong Zhang, Jing Wang, Yingtong Chen, Chunyuan Li, Hongmei Jing

Blood (2024) 144 (Supplement 1): 5753.

https://doi.org/10.1182/blood-2024-204870

Published: 2024

Journal Articles

A Comprehensive Stratification Integrated the Clinical, Pathological, and Molecular Biological Features to Distinguish High-Risk Mantle Cell Lymphoma

Ping Yang, Chunyuan Li, Shuozi Liu, Yuan Yang, Weilong Zhang, Jing Wang, Yingtong Chen, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6305.

https://doi.org/10.1182/blood-2024-205002

Published: 2024

Journal Articles

Polatuzumab Vedotin As an Effective Salvage Therapy for Relapsed/Refractory Mantle Cell Lymphoma Resistantance to BTK and BCL Inhibitors

Ping Yang, Chunyuan Li, Yuan Yang, Shuozi Liu, Jing Wang, Yingtong Chen, Weilong Zhang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6303.

https://doi.org/10.1182/blood-2024-204939

Published: 2024

Journal Articles

TP53 Mutation Heterogeneity Reveals Distinct Prognoses in Mantle Cell Lymphoma

Shuozi Liu, Shaowei Zhou, Weilong Zhang, Jing Wang, Lingli Wang, Chunyuan Li, Yingtong Chen, Wenxin Qi, Ping Yang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6301.

https://doi.org/10.1182/blood-2024-204877

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phase I study of a CD19-directed CAR-T cell therapy for Relapsed/refractory mantle cell lymphomas(MCL)

Short-term follow-up results of ultra-low-dose radiotherapy for indolent B-cell lymphoma

Genomic characterization uncovers molecular subtypes in Mantle Cell Lymphoma

Heterogeneous TP53 mutation subtypes define prognostic classification in Mantle Cell Lymphoma

Analysis of factors associated with clinical response in glofitamab's treatment of relapsed or refractory (R/R) large B-cell lymphoma

Efficacy and safety of zanubrutinib combined with reduced-dose bendamustine and Rituximab for eldly Mantle Cell Lymphoma: A retrospective analysis

Prognostic and therapeutic implications of the immune landscape in Mantle Cell Lymphoma

Single-cell dissection of pathogenic T-cell response to tacrolimus in immune thrombocytopenia

Teriflunomide, an oral dihydroorotate dehydrogenase inhibitor, in immune thrombocytopenia

Robust assessment of early MRD levels could further improve treatment outcomes in low-risk patients of pediatric acute lymphoblastic leukemia: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL Study

The efficacy of Obinutuzumab , zanubrutinib combined with pomalidomide and Venetoclax for the treatment of high-risk mutated Mantle Cell Lymphoma (MCL): A prospective, open-label, single-arm study

Therapeutic preclinical study on the synergy between CD73 inhibitors and selinexor for managing multiple myeloma

Baricitinib reveals LGALS3BP as a novel pathogenic factor and therapeutic target in immune thrombocytopenia

Imaging Activated Innate Immune Myeloid Cells in Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-Cell Therapy

Clinical Application for Modification of the 2022 European Leukemianet Genetic Risk Stratification in Pediatric Acute Myeloid Leukemia

Selinexor Synergizes with Decitabine in Mantle Cell Lymphoma through MAPK Signaling Pathway

UHRF1 Is a Promising Therapy Target in Aggressive Mantle Cell Lymphoma

A Comprehensive Stratification Integrated the Clinical, Pathological, and Molecular Biological Features to Distinguish High-Risk Mantle Cell Lymphoma

Polatuzumab Vedotin As an Effective Salvage Therapy for Relapsed/Refractory Mantle Cell Lymphoma Resistantance to BTK and BCL Inhibitors

TP53 Mutation Heterogeneity Reveals Distinct Prognoses in Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only